Keyphrases
Receptor Downregulation
100%
Insulin-like Growth Factor 1 Receptor (IGF1R)
100%
Ovarian Cancer
100%
Isoform-selective Inhibitor
100%
Phosphatidylinositol 4-phosphate 5-kinase (PIP5K)
100%
PIK3CA
100%
PI3Ki
50%
Ovarian Cancer Patients
33%
Mammalian Target of Rapamycin (mTOR)
33%
Ovarian Cancer Cells
33%
Molecular Mechanism
16%
Tumor
16%
Clinical Trials
16%
Knockdown
16%
Receptor Antagonist
16%
In Vitro Activity
16%
Antitumor Activity
16%
Stable Disease
16%
Genetic Modification
16%
Clinical Evaluation
16%
Autophagy
16%
New Therapeutic Strategies
16%
Acquired Resistance
16%
New Therapeutics
16%
Hyperactivity
16%
Dual Inhibition
16%
Molecular Profile
16%
Sustained Activation
16%
Resistant Cells
16%
Kinase Cascade
16%
Therapeutic Combinations
16%
MTOR Inhibitor
16%
Tumor Cell Proliferation
16%
Taselisib
16%
Medicine and Dentistry
Fibrinogen
100%
Ovarian Cancer
100%
Somatomedin
100%
Receptor Upregulation
100%
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase
100%
Taselisib
100%
Receptor
71%
In Vitro
28%
Clinical Trial
28%
Mammalian Target of Rapamycin
28%
Ovarian Cancer Cell Line
28%
Disease
14%
Neoplasm
14%
Upregulation
14%
Cell Proliferation
14%
Antineoplastic Activity
14%
Tumor Cell
14%
Autophagy
14%
Hyperactivation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Fibrinogen
100%
Somatomedin
100%
Ovary Cancer
100%
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase
100%
Taselisib
100%
Neoplasm
42%
Clinical Trial
28%
Disease
14%
Biochemistry, Genetics and Molecular Biology
Growth Factor
100%
Isoform
100%
Phosphatidylinositol-4,5-bisphosphate 3-Kinase
100%
Receptor Upregulation
100%
Eicosanoid Receptor
83%
Cancer Cell
33%
Clinical Trial
33%
Mammalian Target of Rapamycin
33%
Cell Proliferation
16%
Upregulation
16%
Autophagy
16%
Antineoplastic Activity
16%